Janux Therapeutics (JANX) Enterprise Value (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Enterprise Value of -$956.4 million for Q1 2026, up 5.7% year-over-year from -$904.9 million in Q1 2025, and up 1.05% quarter-over-quarter from -$966.6 million in Q4 2025.
Janux Therapeutics (JANX) Enterprise Value (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Enterprise Value for 7 consecutive years, with -$956.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 5.7% year-over-year to -$956.4 million; the TTM figure through Mar 2026 stood at -$956.4 million (up 5.7% YoY), while the FY2025 annual figure was -$966.6 million, up 5.72% from the prior year.
- Enterprise Value improved to -$956.4 million in Q1 2026 per JANX's latest filing, from -$966.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$303.3 million in Q2 2023 and bottomed at -$1.0 billion in Q4 2024.
- Historically, Enterprise Value has averaged -$623.4 million across 5 years, with a median of -$646.3 million in 2024.
- Annual changes were most pronounced in 2023 — Enterprise Value rose 14.4% — and 2024, when it plunged 197.99%.
- Janux Therapeutics' Enterprise Value stood at -$327.0 million in 2022, then dropped by 5.2% to -$344.0 million in 2023, then slumped by 197.99% to -$1.0 billion in 2024, then rose by 5.72% to -$966.6 million in 2025, then rose by 1.05% to -$956.4 million in 2026.
- Business Quant data shows JANX's Enterprise Value at -$956.4 million in Q1 2026, -$966.6 million in Q4 2025, and -$989.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | -970.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -970.91 Mn |
| Mar 31, 2026 | -956.39 Mn |
| Dec 31, 2025 | -966.57 Mn |
| Sep 30, 2025 | -988.99 Mn |
| Jun 30, 2025 | -996.01 Mn |
| Mar 31, 2025 | -1.01 Bn |
| Dec 31, 2024 | -1.03 Bn |
| Sep 30, 2024 | -658.03 Mn |
| Jun 30, 2024 | -646.29 Mn |
| Mar 31, 2024 | -651.76 Mn |
| Dec 31, 2023 | -344.03 Mn |
| Sep 30, 2023 | -349.71 Mn |
| Jun 30, 2023 | -303.29 Mn |
| Mar 31, 2023 | -316.88 Mn |
| Dec 31, 2022 | -327.02 Mn |
| Sep 30, 2022 | -338.76 Mn |
| Jun 30, 2022 | -354.30 Mn |
| Mar 31, 2022 | -361.20 Mn |
| Dec 31, 2021 | -374.97 Mn |
| Sep 30, 2021 | -387.51 Mn |